Literature DB >> 2895853

Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime.

S Daenen, H de Vries-Hospers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2895853     DOI： 10.1016/s0140-6736(88)91741-2

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

Review 1.  Continuous infusion of beta-lactam antibiotics.

Authors:  W A Craig; S C Ebert
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

2.  Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.

Authors:  William K Lau; David Mercer; Kamal M Itani; David P Nicolau; Joseph L Kuti; Debra Mansfield; Adrian Dana
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  In vitro pharmacodynamics of ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  M Manduru; L B Mihm; R L White; L V Friedrich; P A Flume; J A Bosso
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 4.  Management of antimicrobial use in the intensive care unit.

Authors:  F Alvarez-Lerma; M Palomar; S Grau
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  High-dose continuous infusion beta-lactam antibiotics for the treatment of resistant Pseudomonas aeruginosa infections in immunocompromised patients.

Authors:  Brad Moriyama; Stacey A Henning; Richard Childs; Steven M Holland; Victoria L Anderson; John C Morris; Wyndham H Wilson; George L Drusano; Thomas J Walsh
Journal:  Ann Pharmacother       Date:  2010-04-06       Impact factor: 3.154

6.  Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.

Authors:  J W Mouton; A M Horrevorts; P G Mulder; E P Prens; M F Michel
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

7.  Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia.

Authors:  S Daenen; Z Erjavec; D R Uges; H G De Vries-Hospers; P De Jonge; M R Halie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-03       Impact factor: 3.267

8.  Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.

Authors:  A S Benko; D M Cappelletty; J A Kruse; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

Review 9.  Impact of dosage schedule of antibiotics on the treatment of serious infections.

Authors:  I A Bakker-Woudenberg; R Roosendaal
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 10.  Ceftazidime. An update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C P Rains; H M Bryson; D H Peters
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.